In the continued expansion of its intellectual property practice, Goodwin today announced that Carl Morales has joined the firm’s Life Sciences practice, as a partner in the New York office.
“Intellectual property is central to innovation and growth, particularly in life sciences,” said Mitchell Bloom, Global Chair of Life Sciences at Goodwin. “Our globally recognized practice stands out as one of the most comprehensive, specializing in IP-intensive transactions and providing strategic guidance on complex diligence matters that help our clients advance their business objectives. With a strong foundation in both science and law, Carl’s highly impressive work in securing, protecting, and managing patent rights for clients in the biotechnology, chemistry, pharmaceutical, and medical device sectors greatly complements our practice and team. We are delighted to welcome Carl to Goodwin.”
Carl has particular expertise in developing and prosecuting complex patent portfolios for small molecule drug products, including for products involved or expected to be involved in litigation. He devises and executes strategies to secure second and third generation patent coverage that extends pharmaceutical product exclusivity. He also routinely conducts due diligence on life science patent portfolios for a variety of transactions, including licensing deals, acquisitions, investments and royalty purchases. His practice additionally includes pre-litigation case assessments; and preparing patentability, validity, infringement and enforcement opinions. He is experienced in post-grant patent proceedings when product-critical patents are at stake, including reissues, reexaminations and European oppositions.
With more than 240 dedicated lawyers and patent agents across all major life sciences hubs in the US, Europe, and Asia, Goodwin works with life sciences companies throughout the corporate lifecycle – from startup and commercial-stage to maturity – as well as investors, banks, and others in the life sciences ecosystem. The firm understands the unique challenges life science companies face in securing funding, licensing and safeguarding intellectual property, establishing partnerships, bringing new products to market, opening new revenue streams, and protecting existing product lines. The team takes a multidisciplinary approach to address clients’ challenges, drawing on deep expertise across industries – such as technology, healthcare, real estate, and private equity – as well as the full spectrum of relevant practices.